Advertising
Showing 1 to 13 of 13 entries
  • «
  • 1
  • »
PAST TOP PICK
(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Nov 11/10. Up 28.57%.)
biotechnology / pharmaceutical
PAST TOP PICK
(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.
biotechnology / pharmaceutical
TOP PICK
Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.
biotechnology / pharmaceutical
TOP PICK
Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.
biotechnology / pharmaceutical
WEAK BUY
Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.
biotechnology / pharmaceutical
TOP PICK
In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.
biotechnology / pharmaceutical
TOP PICK
They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.
biotechnology / pharmaceutical
TOP PICK
A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments.
biotechnology / pharmaceutical
TOP PICK
biotechnology / pharmaceutical
TOP PICK
Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt.
biotechnology / pharmaceutical
Showing 1 to 13 of 13 entries
  • «
  • 1
  • »

Theragenics Corp(TGX-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Theragenics Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Theragenics Corp(TGX-N) Frequently Asked Questions

What is Theragenics Corp stock symbol?

Theragenics Corp is a OTC stock, trading under the symbol TGX-N on the (). It is usually referred to as or TGX-N

Is Theragenics Corp a buy or a sell?

In the last year, there was no coverage of Theragenics Corp published on Stockchase.

Is Theragenics Corp a good investment or a top pick?

Theragenics Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Theragenics Corp.

Why is Theragenics Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Theragenics Corp worth watching?

In the last year, there was no coverage of Theragenics Corp published on Stockchase.

What is Theragenics Corp stock price?

On , Theragenics Corp (TGX-N) stock closed at a price of $.